Literature DB >> 23079191

Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.

Shivali Gupta1, Nisha Jain Garg.   

Abstract

In this study, we have characterized the immune mechanisms elicited by antigenic candidates, TcG2 and TcG4, delivered by a DNA-prime/MVA-boost approach, and evaluated the host responses to Trypanosoma cruzi infection in C57BL/6 mice. Immunization of mice with antigenic candidates elicited antigen-specific, high-avidity, trypanolytic antibody response (IgG2b>IgG1) and CD8(+)T cells that exhibited type-1 cytolytic effector (CD8(+)CD107a(+)IFN-γ(+)Perforin(+)) phenotype. The extent of TcG2-dependent type 1 B and T cell immunity was higher than that noted in TcG4-immunized mice, and expanded accordingly in response to challenge infection with T. cruzi. The progression of chronic phase in immunized mice was associated with persistence of IgGs, 55-90% reduction in the frequency of proinflammatory (IFN-γ(+) or TNF-α(+)) CD8(+)T cells, and an increase or emergence of immunoregulatory (IL-10(+)) CD4/CD8 T cells. The tissue parasitism, infiltration of inflammatory infiltrate, parasite persistence, and fibrosis were decreased by 82-92% in heart and skeletal muscle of immunized/chronically infected mice. Control mice exhibited a significantly low antibody response, consistent activation of effector CD8(+)T cells dominated by pro-inflammatory phenotype and mixed cytokine profile (IFN-γ+TNF-α>IL-4+IL-10), parasite persistence and pathologic damage in chagasic hearts. We conclude that delivery of TcG2 or TcG4 by DNA-rMVA approach elicits effective antibody and CD8(+)T cell mediated immunity against T. cruzi and Chagas disease. The emergence of type 2 cytokine and T cell response in chronic phase was indicative of prevention of clinical disease.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079191      PMCID: PMC3508390          DOI: 10.1016/j.vaccine.2012.10.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  Maintenance of serological memory by polyclonal activation of human memory B cells.

Authors:  Nadia L Bernasconi; Elisabetta Traggiai; Antonio Lanzavecchia
Journal:  Science       Date:  2002-12-13       Impact factor: 47.728

2.  NADPH oxidase inhibition ameliorates Trypanosoma cruzi-induced myocarditis during Chagas disease.

Authors:  Monisha Dhiman; Nisha Jain Garg
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

3.  Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.

Authors:  Philip Bejon; Jedidah Mwacharo; Oscar K Kai; Stephen Todryk; Sheila Keating; Trudie Lang; Sarah C Gilbert; Norbert Peshu; Kevin Marsh; Adrian V S Hill
Journal:  Vaccine       Date:  2006-03-31       Impact factor: 3.641

4.  Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease.

Authors:  Walderez Ornelas Dutra; Cristiane Alves Silva Menezes; Fernanda Nobre Amaral Villani; Germano Carneiro da Costa; Alexandre Barcelos Morais da Silveira; Débora d'Avila Reis; Kenneth J Gollob
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

5.  Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease.

Authors:  F D Cordeiro; O A Martins-Filho; M O Da Costa Rocha; S J Adad; R Corrêa-Oliveira; A J Romanha
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

Review 6.  Vaccine development against Trypanosoma cruzi and Chagas disease.

Authors:  Juan C Vázquez-Chagoyán; Shivali Gupta; Nisha Jain Garg
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

7.  Tissue-specific oxidative imbalance and mitochondrial dysfunction during Trypanosoma cruzi infection in mice.

Authors:  Jian-Jun Wen; Monisha Dhiman; Elbert B Whorton; Nisha Jain Garg
Journal:  Microbes Infect       Date:  2008-07-16       Impact factor: 2.700

8.  Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

Review 9.  Chagas heart disease pathogenesis: one mechanism or many?

Authors:  Kevin M Bonney; David M Engman
Journal:  Curr Mol Med       Date:  2008-09       Impact factor: 2.222

10.  Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs.

Authors:  José E Aparicio-Burgos; Laucel Ochoa-García; José Antonio Zepeda-Escobar; Shivali Gupta; Monisha Dhiman; José Simón Martínez; Roberto Montes de Oca-Jiménez; Margarita Val Arreola; Alberto Barbabosa-Pliego; Juan C Vázquez-Chagoyán; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2011-05-17
View more
  11 in total

1.  Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease.

Authors:  Christopher A Seid; Kathryn M Jones; Jeroen Pollet; Brian Keegan; Elissa Hudspeth; Molly Hammond; Junfei Wei; C Patrick McAtee; Leroy Versteeg; Amanda Gutierrez; Zhuyun Liu; Bin Zhan; Jonathan L Respress; Ulrich Strych; Maria Elena Bottazzi; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2016-10-13       Impact factor: 3.452

2.  A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.

Authors:  Meagan A Barry; Qian Wang; Kathryn M Jones; Michael J Heffernan; Munir H Buhaya; Coreen M Beaumier; Brian P Keegan; Bin Zhan; Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

3.  Serum-mediated activation of macrophages reflects TcVac2 vaccine efficacy against Chagas disease.

Authors:  Shivali Gupta; Trevor S Silva; Jessica E Osizugbo; Laura Tucker; Heidi M Spratt; Nisha J Garg
Journal:  Infect Immun       Date:  2014-01-13       Impact factor: 3.441

Review 4.  Developments in the management of Chagas cardiomyopathy.

Authors:  Herbert B Tanowitz; Fabiana S Machado; David C Spray; Joel M Friedman; Oren S Weiss; Jose N Lora; Jyothi Nagajyothi; Diego N Moraes; Nisha Jain Garg; Maria Carmo P Nunes; Antonio Luiz P Ribeiro
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-10-23

5.  Therapeutic Efficacy of a Subunit Vaccine in Controlling Chronic Trypanosoma cruzi Infection and Chagas Disease Is Enhanced by Glutathione Peroxidase Over-Expression.

Authors:  Shivali Gupta; Charity Smith; Sarah Auclair; Anahi De Jesus Delgadillo; Nisha Jain Garg
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

6.  A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi.

Authors:  Shivali Gupta; Nisha J Garg
Journal:  PLoS Pathog       Date:  2015-05-07       Impact factor: 6.823

7.  Evaluation of pathogen P21 protein as a potential modulator of the protective immunity induced by Trypanosoma cruzi attenuated parasites.

Authors:  Cecilia Pérez Brandán; Andrea C Mesias; Leonardo Acuña; Thaise Lara Teixeira; Claudio Vieira da Silva
Journal:  Mem Inst Oswaldo Cruz       Date:  2019-05-20       Impact factor: 2.743

8.  TcG2/TcG4 DNA Vaccine Induces Th1 Immunity Against Acute Trypanosoma cruzi Infection: Adjuvant and Antigenic Effects of Heterologous T. rangeli Booster Immunization.

Authors:  Shivali Gupta; Berenice Salgado-Jiménez; Nandadeva Lokugamage; Juan Carlos Vázquez-Chagoyán; Nisha Jain Garg
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

9.  Antigenicity and diagnostic potential of vaccine candidates in human Chagas disease.

Authors:  Shivali Gupta; Xianxiu Wan; Maria P Zago; Valena C Martinez Sellers; Trevor S Silva; Dadjah Assiah; Monisha Dhiman; Sonia Nuñez; John R Petersen; Juan C Vázquez-Chagoyán; Jose G Estrada-Franco; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2013-01-17

10.  TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.